Search results
Showing 1 result for zanubrutinib with obinutuzumab for treating relapsed or refractory b-cell follicular lymphoma after 2 or more treatments (terminated appraisal)
NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is because BeiGene has requested a delay to the evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA978